Literature DB >> 14981101

Better survival with interleukin-2-based regimens? Possibly only in highly selected patients.

Sylvie Négrier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14981101     DOI： 10.1200/JCO.2004.01.998

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

Review 1.  Immunotherapy in metastatic renal cell carcinoma.

Authors:  Karl Rohrmann; Michael Staehler; Nikolas Haseke; Alexander Bachmann; Christian G Stief; Michael Siebels
Journal:  World J Urol       Date:  2005-04-02       Impact factor: 4.226

2.  [Renal cell carcinoma].

Authors:  A Haferkamp; D Rohde; S C Müller; H Rübben; M Hohenfellner
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

Review 3.  [Therapy strategies for advanced renal cell carcinoma].

Authors:  M Staehler; N Haseke; G Schöppler; T Stadler; C Adam; C G Stief
Journal:  Urologe A       Date:  2006-01       Impact factor: 0.639

4.  Interleukin-2 in the treatment of unresectable or metastatic renal cell cancer: a systematic review and practice guideline.

Authors:  Sebastien Hotte; Tricia Waldron; Christina Canil; Eric Winquist
Journal:  Can Urol Assoc J       Date:  2007-03       Impact factor: 1.862

5.  Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma.

Authors:  Anil K Kapoor; Sébastien J Hotte
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

Review 6.  Current status and perspective of antiangiogenic therapy for cancer: urinary cancer.

Authors:  Shigeru Kanda; Yasuyoshi Miyata; Hiroshi Kanetake
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.850
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.